The initial success of Viagra undeniably reshaped the pharmaceutical landscape, but betting in companies heavily reliant on generic versions presents a uncertain picture. While early earnings were substantial, the end of patents and the rise of cheaper alternatives have eroded market share. Thus, a thorough evaluation of ongoing financial performan